期刊文献+

术前尿可溶性Fas表达在预测非肌层浸润性膀胱癌复发中的价值 被引量:3

Value of detection of preoperative urinary soluble Fas expression in predicting the recurrence of non-muscle invasive bladder cancer
暂未订购
导出
摘要 目的:探讨术前尿可溶性Fas(soluble Fas,sFas)表达在预测非肌层浸润性膀胱癌(non-muscle invasive bladder cancer,NMIBC)复发中的作用。方法:采用前瞻性研究方法,选取2008年1月至2011年4月期间经手术病理确诊的128例NMIBC患者,采用ELISA法测定手术前尿sFas值。结合多项临床病理参数进行非参数统计分析,采用Kaplan-Meier生存曲线分析尿sFas水平与NMIBC患者复发之间的关系,采用Cox比例风险模型进行分析,筛选影响NMIBC预后的独立因素,构建计算预后指数(prognosis index,PI)的公式。结果:NMIBC患者尿s Fas值随着病理分期、分级、欧洲癌症研究与治疗组织(EORTC)膀胱癌预后风险评分表评分的增加而增高(P<0.05),与年龄和性别无关(P>0.05)。Kaplan-Meier生存曲线提示,与低sFas组比较,高sFas组的NMIBC复发率明显增高(P<0.001)。经Cox回归模型分析,尿sFas值、EORTC评分是影响NMIBC预后的独立因素(P<0.05),计算得到PI公式为0.004×尿sFas值+1.179×EORTC评分。结论:检测尿液sFas表达是预测NMIBC复发的有用指标,值得深入研究。 Objective: To investigate the clinical value of detection of preoperative urinary soluble Fas (sFas) expression in predicting the recurrence of non-muscle invasive bladder cancer (NMIBC). Methods: We performed a prospective research, which included 128 cases with NMIBC from January 2008 to April 2011. Expression levels of sFas in urine, which was saved at the first morning from preoperative NMIBC patients, were analyzed by ELISA. Clinical and pathological data, European Organization for Research and Treatment of Cancer (EORTC) risk group category, follow-up data and urinary sFas values were collected from each patient, and each prognostic outcome was evaluated by statistical analysis of non-parametric test. Urinary sFas values and recurrence-free probabilities were estimated by the Kaplan-Meier method and compared by the log rank test. Cox proportional hazards regression models were performed to determine the independent predictors of NMIBC recurrence. The prognosis index (PI) was established. Results: The urinary sFas level was significantly elevated in the NMIBC cases with a higher stage or grade or high-risk EORTC group category than in those with a lower stage or grade or low-risk EORTC group category (each P〈0.05), regardless of age or gender (P〉0.05). Kaplan-Meier analysis revealed a significant increase in incidence of recurrence in the NMIBC patients with high sFas levels in the urine (P〈0.001). According to Cox regression analysis, the urinary sFas level and EORTC risk group category (each P〈0.05) were the independent predictors of NMIBC recurrence. Based on the outcome of Cox regression, the formula of PI=(0.004×sFas value+1.179×EORTC score) was established. Conclusion: Our study indicates that urinary sFas test may help to identify NMIBC patients at risk of tumor recurrence and it deserves further research.
出处 《中南大学学报(医学版)》 CAS CSCD 北大核心 2016年第1期24-29,共6页 Journal of Central South University :Medical Science
关键词 可溶性FAS 膀胱癌 肿瘤标志物 预后 尿 soluble Fas bladder cancer tumor marker prognosis urine
  • 相关文献

参考文献11

  • 1孙二琳,范晓东,韩瑞发,牛远杰.重组人干扰素α-2b-卡介苗对膀胱癌MB49细胞的体外作用[J].中华肿瘤杂志,2010,32(4):244-248. 被引量:3
  • 2杨惠祥,高靖,王振潮,翟秀芬.尿中可溶性Fas在膀胱癌诊断中的价值[J].中国现代医学杂志,2013,23(7):38-41. 被引量:3
  • 3Svatek RS, Herman MP, Lotan Y, et al. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer[J]. Cancer, 2006, 106(8): 1701-1707.
  • 4Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update[J]. Eur Urol, 2011, $9(6): 997-1008.
  • 5Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu~rin: multivariate analysis of data from four randomized CUETO trials[J]. Eur Urol, 2008, 53(S): 992-1001.
  • 6Guo CL, Yang XH, Cheng'vV, et al. Expression of Fas/FasL in CD8+ T and CDJ+ FoxpJ+ Treg cells--elationship with apoptosis of circulating CD8+ T cells in hepatocellular carcinoma patients[J]. Asian PacJ Cancer Prey, 2014, 1S(6): 2613-2618.
  • 7Dai XL, Zhou SL, Q iu J, et al. Correlated expression of Fas, NF- kappaB, and VEGF-C in infiltrating ductal carcinoma of the breast[J]. EurJ Gynaecol Oncol, 2012, 33(6): 633-639.
  • 8Codony-Servat J, Garcia-Albeniz X, Pericay C, et al. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patientswith advanced colorectal cancer[J]. Med Oncol, 2013, 30(1): 428.
  • 9Mizutani Y, Yoshida O, Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer[J]. J Urol, 1998, 160(2): 571-$76.
  • 10Perabo FG, Mattes RH, Wirger A, et al. Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo[J]. Urol Oncol, 2001, 6(4): 163- 169.

二级参考文献12

  • 1刘春雨,韩瑞发,马腾骧,畅继武,韩育植,隋志芳.phIFN-α-2B穿梭质粒在卡介苗中的表达[J].中华泌尿外科杂志,2006,27(S1):12-14. 被引量:8
  • 2何小军,全晓明,沈阳,陶德定,龚建平.体外Fas介导肿瘤细胞凋亡过程中cyclins/CDKs的变化规律及调节机制[J].肿瘤,2010,30(10):807-814. 被引量:1
  • 3Rajala P,Kaasinen E,Rintala E,et al.Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferonalpha.Urol Res,1992,20:215-217.
  • 4Moriwaki Y,Begum NA,Kobayashi M,et al.Mycobacterium bovis Bacillus Calmette-Guerin and its cell wall complex induce a novel lysosomal membrane protein,SIMPLE,that bridges the missing link between lipopolysaccharide and p53-inducible gene,LITAF(PIG7),and estrogen-inducible gene,EET-1.J Biol Chem,2001,276:23065-23076.
  • 5Ryll R,Watanabe K,Fujiwara N,et al.Mycobacterial cord factor,but not sulfolipid,causes depletion of NKT celts and upregulation of CD1d1 on murine macrophages.Microbes Infect,2001,3:611-619.
  • 6O'Donnell MA,Luo Y,Chen X,et al.Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin.J Immunol,1999,163:4246-4252.
  • 7Shankaran V,Ikeda H,Bruce AT,et al.IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.Nature,2001,410:1107-1111.
  • 8D'Orazio SE,Halme DG,Ploegh HL,et al.Class Ⅰa MHC-deficient BALB/c mice generate CD8 + T cell-mediated protective immunity against Listena monocytogenes infection.J Immunol,2003,171:291-298.
  • 9杨惠祥,高靖,王志勇,于满.两种膀胱癌抗原致敏方式对树突状细胞分泌IL-12的影响和意义[J].中国现代医学杂志,2010,20(22):3380-3382. 被引量:1
  • 10刘尚莹,曹晓明,武学清,胡佩胜.α-2b干扰素膀胱灌注预防表浅性膀胱肿瘤术后复发[J].中华肿瘤杂志,2000,22(6):522-522. 被引量:6

共引文献4

同被引文献24

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部